Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company’s recent patent applications. US patent application 12/005653, “Short Bioactive Peptides for Cellular and Immunological Modulation,” covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.
Striking Skin Care and Heptapeptide-7 are specifically designed for peri- and post-menopausal skin. Clinical data demonstrating the significant benefits of Striking Skin Care has been accepted for publication in a leading dermatology journal in early 2010 and will be presented at a number of 2010 dermatology and aesthetic conferences including the 8th Annual Meeting of the Society of Dermatology Skin Care Specialists in Miami in March. In addition, Heptapeptide-7 will also be featured in a technology innovation article in the December issue of the trade journal HAPPI.
Helix BioMedix Chief Scientific Officer Dr. Tim Falla commented, “We pride ourselves on the company’s strong and growing IP portfolio and greatly appreciate the dermatology community’s enthusiastic response to its commercialization through Striking Skin Care with SmartPeptides. Our extensive library now comprises more than 80 issued and pending US and foreign patents covering the largest peptide portfolio of its kind.”